Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03933696 · ClinicalTrials.gov registry record · NA

Light, Metabolic Syndrome and Alzheimer's Disease - Aim 2

A NA study, sponsored by Icahn School of Medicine at Mount Sinai.

Completed
Registry status
NA
Development phase
25
Enrollment target

NCT03933696: Completed NA study, sponsored by Icahn School of Medicine at Mount Sinai.

NCT03933696 is a NA study that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 25 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03933696, a NA study, has completed, sponsored by Icahn School of Medicine at Mount Sinai.

COMPLETED
Registry status
NA
Development phase
25 participants
Enrollment target

Study Summary

To test the long term effect of a light treatment on cognition, sleep and metabolism in patients with Mild cognitive impairment (MCI) or mild Alzheimer's disease or related dementia (ADRD).

Primary Outcome

Changes in glucose homeostasis and insulin sensitivity will be measured using the Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT).

Interventions

  • DEVICE Tailored Lighting Intervention

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2019-01-02
Est. Completion 2025-05-31
Phase NA

What the finished NCT03933696 record still lists

NCT03933696 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 1 intervention - of which Tailored Lighting Intervention is the first listed.

NCT03933696 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03933696 about?

NCT03933696 is a clinical study titled "Light, Metabolic Syndrome and Alzheimer's Disease - Aim 2". To test the long term effect of a light treatment on cognition, sleep and metabolism in patients with Mild cognitive impairment (MCI) or mild Alzheimer's disease or related dementia (ADRD).

What is the current status of trial NCT03933696?

This trial is currently completed. It is a NA study. The enrollment target is 25 participants. The study started on 2019-01-02. Estimated completion is 2025-05-31.

What interventions are being tested in trial NCT03933696?

The interventions under investigation include: Tailored Lighting Intervention (DEVICE).

Who is sponsoring clinical trial NCT03933696?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03933696's enrollment target sits among peer trials

25 1712th of 2000 higher than 265 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01166854 · 25 participants

    Characterization of Familial Myopathy and Paget Disease of Bone

  • NCT01913106 · 25 participants · Phase 1

    HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer

  • NCT02138669 · 25 participants · NA

    Intacs Prescription Inserts for Keratoconus Patients

  • NCT02174549 · 25 participants · Phase 1

    Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03933696, the US trial registry maintained by the National Library of Medicine. NCT03933696 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.